Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
199 Leser
Artikel bewerten:
(0)

Micro-Tech Endoscopy USA Hires Vice President of Sales to Maximize the Availability of Exceptional Scope-Based Medical Devices

Scott VanderMeer Adds to the Company's Experienced Team to Scale Global Sales Operations

ANN ARBOR, MI / ACCESSWIRE / May 10, 2022 / Micro-Tech Endoscopy, a global medtech company that develops and supplies diagnostic and therapeutic devices in the gastroenterology space, has appointed Scott VanderMeer as its U.S. Vice President of Sales.

TrailRunner International, Monday, May 9, 2022, Press release picture

Scott VanderMeer

VanderMeer joins the patient-centric and experienced Micro-Tech leadership team to maximize the company's global growth trajectory. Micro-Tech currently serves the American, European, Latin American, Asian and Canadian markets and has brought over 34 products to market since 2020. From 2020 to 2021, Micro-Tech notably saw 50% YOY growth in the U.S.

This increase in growth, despite the challenges brought on by COVID-19, can be attributed to the company's ability to design, develop, and deploy superior tools that improve the effectiveness, safety, and potential of scope-based care. Micro-Tech collaborates closely with physicians to deliver devices that meet existing needs, pushing the boundaries on the types of procedures that can be performed in a more minimally invasive and cost-effective manner.

"It's exciting to join a team with such disruptive momentum," VanderMeer said. "Micro-Tech's commitment to improving the patient experience, offering a hassle-free medical device purchasing experience, and enabling providers to sustain their margins is a win-win situation for the provider and the patient."

VanderMeer comes to Micro-Tech from Clarius Mobile Health, where he led global sales strategy and annual operating plan execution to double the size of the sales organization, resulting in revenue growth from $6M to $24M in FY21. Previously, he served multiple positions at Verathon Medical over 15 years, culminating in the role of Vice President, U.S. Sales & Commercial Operations. In his role at Verathon, Scott scaled the U.S. organization to deliver 46% growth, $190M in revenue, and successfully commercialized 7 new class I and II medical products.

"Scott is a results-driven leader in the medical device industry, bringing extensive experience scaling teams to meet the demands of our value innovation culture," said Micro-Tech USA President Chris Li. "Scott's ability to make our technology available for use in more procedures globally has the power to give more patients the greatest chance of a positive outcome. Together we can positively impact patient health at an unprecedented rate."

For more information about Micro-Tech Endoscopy and its products, visit mtendoscopy.com.

About Micro-Tech Endoscopy USA

Since 2000, Micro-Tech Endoscopy has been focused on creating top-quality products for endoscopic diagnosis, and therapeutic medical devices that allow physicians to provide the highest level of care. By partnering with doctors dedicated to innovation, Micro-Tech is committed to bringing better devices to market, with unparalleled speed, at an economical price, and without the burden of contracts. Micro-Tech does not compromise on quality and does not believe customers should either.

Micro-Tech Endoscopy has operations in America, Asia, and Europe and leverages this global reach to rapidly commercialize and refine the products it brings to its clinician partners. Micro-Tech's team has a wealth of experience in the field and in-depth understanding of both product and use cases.

With the health care industry transforming rapidly, Micro-Tech Endoscopy is dedicated to setting the pace as a disruptor. Micro-Tech is more than a medical technology company, it is building a community of healthcare innovators and making health care more value-driven.

Micro-Tech Endoscopy USA, Inc.

Stephanie Reynolds / Emmie McMinn
stephanie.reynolds@trailrunnerint.com
emmie.mcminn@trailrunnerint.com

SOURCE: Micro-Tech Endoscopy



View source version on accesswire.com:
https://www.accesswire.com/700706/Micro-Tech-Endoscopy-USA-Hires-Vice-President-of-Sales-to-Maximize-the-Availability-of-Exceptional-Scope-Based-Medical-Devices

© 2022 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.